KN-nummer 3002 15 00 Immunologiska produkter som föreligger i avdelade doser eller i former eller…

Taric-nummer (10 siffror): 1

Ursprungsland, förmånstull och nästa steg ›

Exempel ur EU:s databas över bindande klassificeringsbesked (BKB/BTI). Beskeden gäller bara för sin innehavare och många har löpt ut — se dem som vägledning, inte som beslut för din vara.

• SUPERCHEMIBLOCK HETEROPHILE BLOCKING AGENT IT IS A HIGHLY PURIFIED IMMUNOGLOBULINS WITH PROPRIETARY AUGMENTING REAGENTS, A NON-STERILE LIQUID

  3002 15 00 · IE 2017 · IE17-nt-14-4825-04

• A REAGENT RED BLOOD CELL PRODUCT CONSISTING OF BLOOD FRACTION OF HUMAN ORIGIN FOR USE IN ANTIBODY DETECTION THE PRODUCT IS PRESENTED IN A 10ML VIAL

  3002 15 00 · IE 2017 · IE16NT-14-4772-05

• (ENB-0040), ALSO KNOWN AS STRENSIQ, IS A TARGETED ENZYME REPLACEMENT THERAPY DESIGNED TO ADDRESS THE UNDERLYING CAUSE OF HYPOPHOSPHATASIA (HPP) BY NORMALIZING THE GENETICALLY DEFECTIVE METABOLIC PROCESS, AND PREVENTING OR REVERSING THE SEVERE AND LIFE-THREATENING COMPLICATIONS OF LIFE-LONG DYSREGULATED MINERAL METABOLISM. ITS MAIN COMPONENT ASFOTASE ALFA IS A RECOMBINANT FUSION PROTEIN COMPRISED…

  3002 15 00 · GB 2017 · GB503413985

• REAGENT RED BLOOD CELL PRODUCT CONSISTING OF BLOOD FRACTION OF HUMAN ORIGIN FOR USE IN ANTIBODY DETECTION THE PRODUCT IS PRESENTED IN 3 VIALS

  3002 15 00 · IE 2017 · IE16NT-14-4772-01

• SOLIRIS IS A THERAPY SPECIFICALLY TESTED AND APPROVED FOR THE TREATMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), AN ULTRA-RARE, LIFE-THREATENING BLOOD DISORDER. SOLIRIS HAS BEEN APPROVED FOR THE TREATMENT OF PATIENTS WITH PNH IN NEARLY 50 COUNTRIES WORLDWIDE. SOLIRIS 300 MG/30ML IS A FORMULATION OF ECULIZUMAB WHICH IS A RECOMBINANT HUMANIZED MONOCLONAL IGG2/4;κ ANTIBODY…

  3002 15 00 · GB 2017 · GB503413691